This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Hanhua Huang, PhD
Vice President, Biology at Avidity Biosciences


Scientist with 20 years of industrial experience in leading multi-disciplinary early drug discovery and development teams in oncology, immuno-oncology, pain, and muscular diseases using various therapeutic moieties, such as peptides, oligonucleotides, antibody conjugates and nanoparticles. At Avidity, Hanhua leads teams to develop targeted siRNA nanoparticles and antibody oligo conjugates for immune cells, cancer cells, and muscle cells for various indications.

Agenda Sessions

  • Recent Progress with Antibody Oligonucleotide Conjugates (AOCs)